Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, April 25, 2024
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
[ Thu, Apr 25th 2024
] - WOPRAI
Emily Bodnar Reiterated (ACRV) at Strong Buy and Held Target at $20 on, Apr 25th, 2024
Emily Bodnar of HC Wainwright & Co., Reiterated "Acrivon Therapeutics, Inc." (ACRV) at Strong Buy and Held Target at $20 on, Apr 25th, 2024.
Emily has made no other calls on ACRV in the last 4 months.
There are 2 other peers that have a rating on ACRV. Out of the 2 peers that are also analyzing ACRV, 0 agree with Emily's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Emily
- Aydin Huseynov of "Ladenburg Thalmann" Maintained at Strong Buy with Decreased Target to $14 on, Friday, April 5th, 2024
- Etzer Darout of "BMO Capital" Reiterated at Buy and Held Target at $18 on, Monday, April 1st, 2024
